Yali Hu1,2, Kunpeng Zhang1, Xingyao Zhu1, Xiuyan Zheng1, Chao Wang1, Xiao Niu1, Teng Jiang1, Xinhua Ji1, Weilin Zhao1, Lijuan Pang1, Yan Qi1, Feng Li1,3, Li Li4, Zhiping Xu4, Wenyi Gu4, Hong Zou1. 1. Department of Pathology, The First Affiliated Hospital, School of Medicine, Shihezi University, Key Laboratory of Xinjiang Endemic and Ethnic Diseases of the Ministry of Education of China, Xinjiang, 832002, People's Republic of China. 2. Department of Oncology, Yongcheng People's Hospital, Henan, 476600, People's Republic of China. 3. Department of Pathology, Beijing Chaoyang Hospital, Capital Medical University, Beijing, 10000, People's Republic of China. 4. Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Queensland, 4072, Australia.
Abstract
BACKGROUND: Colon cancer is a top lethal cancer in man and women worldwide and drug resistance is the major cause of cancer-related death. Combinational therapy and drug delivery with nanoparticles have been shown to effectively overcome drug resistance in many cancers. We previously reported that nanoemulsion (NE) loaded paclitaxel (PTX) and BEZ235 could synergistically inhibit colon cancer cell growth. PURPOSE: To investigate whether NE loaded PTX and BEZ235 can overcome drug resistance and synergistically inhibit drug-resistant colon cancer cell growth in vitro and in vivo. METHODS: The in vitro treatment effect on cell viability was assayed using CCK8 kit, cell morphological change was detected by β-tubulin immunofluorescence staining, drug resistance-related proteins were analyzed by Western blotting, and in vivo tumor growth test was performed in nude mice xeno-transplanted with 2 drug-resistant colon cancer cell lines HCT116-LOHP and HT29-DDP. RESULTS: Both cell lines were sensitive to PTX but relatively insensitive to BEZ235. PTX combined with BEZ235 synergistically inhibited the proliferation of both cell lines. Nanoemulsion loaded PTX (NE-PTX) reduced the IC50 of PTX to approximately 2/5 of free PTX, indicating a high inhibitory efficacy of NE-PTX. When NE-PTX combined with a low concentration of BEZ235 (50 nM), the IC50 was decreased to approximately 2/3 of free PTX. Moreover, NE-PTX+BEZ235 treatment increased apoptosis, decreased Pgp and ABCC1 expression, and reduced tumor weights compared to the single drug treatment and the control group. These results suggest that nanoemulsion loaded PTX+BEZ235 can overcome drug resistance and improve the inhibitory effect on cancer cell proliferation and tumor growth. CONCLUSION: Our study thus provides a possible new approach to treat colon cancer patients with drug resistance.
BACKGROUND: Colon cancer is a top lethal cancer in man and women worldwide and drug resistance is the major cause of cancer-related death. Combinational therapy and drug delivery with nanoparticles have been shown to effectively overcome drug resistance in many cancers. We previously reported that nanoemulsion (NE) loaded paclitaxel (PTX) and BEZ235 could synergistically inhibit colon cancer cell growth. PURPOSE: To investigate whether NE loaded PTX and BEZ235 can overcome drug resistance and synergistically inhibit drug-resistant colon cancer cell growth in vitro and in vivo. METHODS: The in vitro treatment effect on cell viability was assayed using CCK8 kit, cell morphological change was detected by β-tubulin immunofluorescence staining, drug resistance-related proteins were analyzed by Western blotting, and in vivo tumor growth test was performed in nude mice xeno-transplanted with 2 drug-resistant colon cancer cell lines HCT116-LOHP and HT29-DDP. RESULTS: Both cell lines were sensitive to PTX but relatively insensitive to BEZ235. PTX combined with BEZ235 synergistically inhibited the proliferation of both cell lines. Nanoemulsion loaded PTX (NE-PTX) reduced the IC50 of PTX to approximately 2/5 of free PTX, indicating a high inhibitory efficacy of NE-PTX. When NE-PTX combined with a low concentration of BEZ235 (50 nM), the IC50 was decreased to approximately 2/3 of free PTX. Moreover, NE-PTX+BEZ235 treatment increased apoptosis, decreased Pgp and ABCC1 expression, and reduced tumor weights compared to the single drug treatment and the control group. These results suggest that nanoemulsion loaded PTX+BEZ235 can overcome drug resistance and improve the inhibitory effect on cancer cell proliferation and tumor growth. CONCLUSION: Our study thus provides a possible new approach to treat colon cancer patients with drug resistance.
Authors: R A Veldhoen; S L Banman; D R Hemmerling; R Odsen; T Simmen; A J Simmonds; D A Underhill; I S Goping Journal: Oncogene Date: 2012-03-19 Impact factor: 9.867
Authors: Faris Alrumaihi; Masood Alam Khan; Ali Yousif Babiker; Mohammed Alsaweed; Faizul Azam; Khaled S Allemailem; Ahmad A Almatroudi; Syed Rizwan Ahamad; Naif AlSuhaymi; Mahdi H Alsugoor; Ahmed N Algefary; Arif Khan Journal: Pharmaceutics Date: 2022-01-20 Impact factor: 6.321
Authors: Faris Alrumaihi; Masood Alam Khan; Ali Yousif Babiker; Mohammed Alsaweed; Faizul Azam; Khaled S Allemailem; Ahmad A Almatroudi; Syed Rizwan Ahamad; Mahdi H Alsugoor; Khloud Nawaf Alharbi; Nahlah Makki Almansour; Arif Khan Journal: Molecules Date: 2022-03-28 Impact factor: 4.411